Heterocyclic thiadiazolidinones, TDZD-8 and TDZD-20, are two non-competitive inhibitors that were developed to inhibit GSK3β [49], and in clinical trials for treatment of Alzheimer's disease [50]. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.